Brief: Immutep Announces Successful Meeting With FDA On TACTI-004 Phase III Trial Design

Immutep

22/07/2024 13:20

July 22 (Reuters) - Immutep Ltd  IMM.AX :
    * IMMUTEP ANNOUNCES SUCCESSFUL MEETING WITH FDA ON PHASE III
DESIGN IN NON-SMALL CELL LUNG CANCER
    * IMMUTEP ANNOUNCES SUCCESSFUL MEETING WITH FDA ON PHASE III
DESIGN IN NON-SMALL CELL LUNG CANCER
    * IMMUTEP LTD: TACTI-004 REGISTRATIONAL TRIAL WILL ENROL
ABOUT 750
PATIENTS REGARDLESS OF PD-L1 EXPRESSION

Source text for Eikon:  ID:nGNX1lkVWP 
Further company coverage:  IMM.AX 

 ((Reuters.Briefs@thomsonreuters.com;))